Laboratory Corporation (LH) to Acquire Monogram Biosciences (MGRM) for $4.55 Per Share
Down)
Laboratory Corporation of America Holdings (NYSE: LH) and Monogram Biosciences, Inc. (NASDAQ: MGRM) have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in a cash tender offer for $4.55 per share for an implied total equity value of approximately $106.7 million, or a total enterprise value of approximately $155 million at March 31, 2009, including net indebtedness.
"The transaction announced today is a significant step in the execution of LabCorp's strategy of leadership in personalized medicine," said David P. King, Chairman and Chief Executive Officer of LabCorp. "Monogram Biosciences, Inc. has an excellent clinical reputation, a market leading infectious disease test, a market leading companion diagnostic, an exciting technology platform for oncology and offers LabCorp a substantial growth opportunity. By utilizing LabCorp's national infrastructure to build on Monogram's already strong sales, we will advance our leadership in infectious disease and cancer testing, companion diagnostics and personalized medicine. We look forward to providing improved offerings to both our and Monogram's current customers."
The acquisition is expected to be approximately $0.12 dilutive to LabCorp's 2009 earnings per share (EPS), including approximately $0.04 of transaction related costs, and slightly accretive to 2010 EPS.
Monogram Biosciences, Inc. (Monogram) is a life sciences company engaged in the development of molecular diagnostic products that guide and target the appropriate treatments. [SM]
"The transaction announced today is a significant step in the execution of LabCorp's strategy of leadership in personalized medicine," said David P. King, Chairman and Chief Executive Officer of LabCorp. "Monogram Biosciences, Inc. has an excellent clinical reputation, a market leading infectious disease test, a market leading companion diagnostic, an exciting technology platform for oncology and offers LabCorp a substantial growth opportunity. By utilizing LabCorp's national infrastructure to build on Monogram's already strong sales, we will advance our leadership in infectious disease and cancer testing, companion diagnostics and personalized medicine. We look forward to providing improved offerings to both our and Monogram's current customers."
The acquisition is expected to be approximately $0.12 dilutive to LabCorp's 2009 earnings per share (EPS), including approximately $0.04 of transaction related costs, and slightly accretive to 2010 EPS.
Monogram Biosciences, Inc. (Monogram) is a life sciences company engaged in the development of molecular diagnostic products that guide and target the appropriate treatments. [SM]
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- CVR Energy (CVI) Hires Jefferies for Sale Process
- Patriot Coal (PCX) shares halted on breaker, bouncing as co. says entered into $625M financing
Create E-mail Alert Related Categories
Hot List, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
